WATCH NOW: Michael Richman on NextCure’s Cancer Treatment Innovations and the Rise of Biotech in Maryland

American Gene Technologies CEO Jeff Galvin sits down with Michael Richman, President & CEO of NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. With four clinical readouts and another IND application for a fourth program expected this year, NextCure is proving to be an emerging leader in immuno-oncology.

Prior to founding NextCure, Richman served as the President and CEO of Amplimmune, which was acquired by MedImmune. Richman has more than 30 years of industry experience and a deep understanding of corporate development. He has been involved in the growth of companies like Chiron (now Novartis), serving in various positions in business development and intellectual property. Richman brings an entrepreneurial spirit to his work, constantly identifying opportunities for growth and expansion and opportunities to invest in groundbreaking technologies. With the current biotech boom occurring in Maryland, Richman provides insight into why Maryland and the Mid-Atlantic has the potential to rival Northern California’s tech hub, Silicon Valley.

Learn more about NextCure:

Learn more about the host and CEO of American Gene Technologies:

About the DNA Valley Series: American Gene’s “DNA Valley” series will highlight cutting-edge cell and gene therapy products, technologies, and platforms in use or in development by leading innovative companies in Maryland. We interview the booming industry’s top executives charging forward with strong leadership and industry knowledge to bring their therapies through the clinic and eventually into patients. This series will cover companies unlocking endless possibilities and creating cell and gene therapy cures for cancers, autoimmune diseases, neurodegenerative diseases, and more. These leaders have overcome challenges to achieve their goals, including workforce competition, manufacturing and supply constraints due to the growing demand for cell and gene therapy, clinical trial delays from the FDA, coronavirus, and more. Hear their stories and learn how they’ve beat the odds and successfully push therapies into a competitive marketplace.

Why “DNA Valley”?: Maryland is home to both the Human Genome Project, which successfully sequenced the human genome, and the National Institutes of Health, the United States’ most prestigious research institution. It is no surprise the state is at the heart of the first cell and gene therapy revolution that is producing cures to previously untreatable diseases. With over 2,700 life science firms, Maryland is on its way to becoming the “DNA Valley” of the United States.

About AGT: American Gene Technologies (AGT) is a clinical-stage, gene and cell therapy company in Rockville, Maryland with a proprietary gene-delivery platform for rapid drug development of infectious diseases, cancers, and inherited disorders. AGT’s mission is to transform people’s lives through genetic medicines that rid the body of disease.